Wesley Sundquist, Ph.D., chair of the Department of Biochemistry, was awarded the 2024 Louisa Gross Horwitz Prize.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Climate change and conflict risk overshadowing efforts to improve people's health, when in reality the issues overlap, Peter ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

It could be a real breakthrough for people at risk for HIV infection: A shot given every 6 months that reduces their risk by a whopping 96%.

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

On Wednesday, RBC Capital adjusted its outlook on Gilead Sciences (NASDAQ:GILD), increasing the price target to $74 from $72 while maintaining a Sector Perform rating. The revision follows positive ...

The revision follows positive data from a recent HIV prevention study. The analyst from RBC Capital noted the impressive efficacy of Gilead's lenacapavir in the PURPOSE-1 PrEP study, which has led ...